TOKYO – Takeda Pharmaceutical Co. Ltd. fell far short of its financial year guidance and forecasts for the next year disappointed analysts. The dismal figures were attributed to higher-than-expected expenditures, and the company released details of a plan to rein in costs through 2017 to improve margins.
“At last year’s earnings meeting, I told you I see light at the end of the tunnel. One year later,...